Literature DB >> 19648300

Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases.

Bolette Soborg1, Morten Ruhwald, Merete Lund Hetland, Søren Jacobsen, Aase Bengaard Andersen, Nils Milman, Vibeke Ostergaard Thomsen, Dorte Vendelbo Jensen, Anders Koch, Jan Wohlfahrt, Pernille Ravn.   

Abstract

OBJECTIVE: To test if Mycobacterium tuberculosis screening results differ among patients with inflammatory disease depending on whether the QuantiFeron TB-Gold test (QFT) or tuberculin skin test (TST) is used; and to evaluate if a possible difference is influenced by the presence of risk factors or immunosuppression.
METHODS: The interferon-gamma response to in vitro stimulation of M. tuberculosis-specific antigens was measured with QFT and results were compared with TST. Associations to bacillus Calmette-Guerin (BCG) vaccination, risk factors, and immunosuppression were analyzed for both tests.
RESULTS: QFT and TST results were available for 294/302 and 241/302 patients, respectively; 234 had results from both tests. Twenty-one (7%) tested positive with QFT and 45 (19%) with TST. A positive QFT was associated with risk factors for M. tuberculosis infection: i.e., birth or upbringing in a TB-endemic area [risk ratio (RR) = 7.8, 95% CI 1.5-18.2, p < 0.001], previous TB treatment (RR 4.7, 95% CI 1.6-13.5, p = 0.005), and any latent TB infection risk factor (RR 4.7, 95% CI 2.1-11.0, p = 0.0002). Treatment with corticosteroids increased the risk for an inconclusive QFT result (RR 4.2, 95% CI 1.6-10.7, p = 0.04) and decreased the risk for a positive TST result (RR 0.4, 95% CI 0.1-1.0, p = 0.04). Agreement between the tests was low (kappa 0.2, 95% CI 0.02-0.3, p = 0.002).
CONCLUSION: The study documented a high degree of discordant positive QFT and TST results. A positive QFT was more closely associated with risk factors for M. tuberculosis infection than the TST. The use of corticosteroids affected test outcome by increasing the risk for an inconclusive QFT result and decreasing the risk for a positive TST result.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19648300     DOI: 10.3899/jrheum.081292

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  Negative effect of immunosuppressive therapy in the performance of the QuantiFERON gold in-tube test in patients with immune-mediated inflammatory diseases.

Authors:  José M Ramos; Mar Masiá; Juan C Rodríguez; Cristina López; Sergio Padilla; Catalina Robledano; Francisco J Navarro-Blasco; Jaime Matarredona; Mariana F García-Sepulcre; Félix Gutiérrez
Journal:  Clin Exp Med       Date:  2012-06-27       Impact factor: 3.984

2.  Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment.

Authors:  Sonia Mínguez; Irene Latorre; Lourdes Mateo; Alicia Lacoma; Jéssica Diaz; Alejandro Olivé; Jose Domínguez
Journal:  Clin Rheumatol       Date:  2012-01-21       Impact factor: 2.980

3.  Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.

Authors:  Boksoon Chang; Hye Yun Park; Kyeongman Jeon; Joong Kyong Ahn; Hoon-Suk Cha; Eun-Mi Koh; Eun-Suk Kang; Won-Jung Koh
Journal:  Clin Rheumatol       Date:  2011-05-10       Impact factor: 2.980

Review 4.  Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis.

Authors:  Qiaoling Ruan; Shu Zhang; Jingwen Ai; Lingyun Shao; Wenhong Zhang
Journal:  Clin Rheumatol       Date:  2014-11-07       Impact factor: 2.980

5.  Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy.

Authors:  Dimitrios Vassilopoulos; Stamatoula Tsikrika; Chrisoula Hatzara; Varvara Podia; Anna Kandili; Nikolaos Stamoulis; Emilia Hadziyannis
Journal:  Clin Vaccine Immunol       Date:  2011-10-12

Review 6.  Rationale of using different biological therapies in rheumatoid arthritis.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Arthritis Res Ther       Date:  2010-08-24       Impact factor: 5.156

7.  QuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life results.

Authors:  Emrah Seyhoglu; Oğuz Abdullah Uyaroğlu; Abdulsamet Erden; Levent Kilic; Omer Karadag; Ali Akdogan; Sule Apras Bilgen; Ihsan Ertenli; Sedat Kiraz; Umut Kalyoncu
Journal:  Clin Rheumatol       Date:  2020-10-15       Impact factor: 2.980

8.  Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease.

Authors:  Arun Swaminath; Nahid Bhadelia; Y Claire Wang
Journal:  Inflamm Bowel Dis       Date:  2013-10       Impact factor: 5.325

9.  Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population.

Authors:  Eun Young Kim; Ju Eun Lim; Ji Ye Jung; Ji Young Son; Kyung Jong Lee; Yoe Wun Yoon; Byung Hoon Park; Jin Wook Moon; Moo Suk Park; Young Sam Kim; Se Kyu Kim; Joon Chang; Young Ae Kang
Journal:  BMC Infect Dis       Date:  2009-12-15       Impact factor: 3.090

10.  The Arctic Human Health Initiative: a legacy of the International Polar Year 2007-2009.

Authors:  Alan J Parkinson
Journal:  Int J Circumpolar Health       Date:  2013-08-05       Impact factor: 1.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.